The Heart Valve Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Heart Valve Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Heart Valve Disease. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Heart Valve Disease - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Heart Valve Disease and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for Heart Valve Disease by nine companies/universities/institutes. The top development phase for Heart Valve Disease is preclinical with five drugs in that stage. The Heart Valve Disease pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Heart Valve Disease pipeline products market are: Abcentra, REDNVIA and Spark Biopharma.

The key targets in the Heart Valve Disease pipeline products market include Apolipoprotein B 100 (ApoB100) , Dipeptidyl Peptidase 4 (ADABP or Adenosine Deaminase Complexing Protein 2 or T Cell Activation Antigen CD26 or TP103 or CD26 or DPP4 or EC 3.4.14.5), and Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase (Cyclizing) or GC or EC 4.6.1.2).

The key mechanisms of action in the Heart Valve Disease pipeline product include Apolipoprotein B 100 (ApoB100) Inhibitor with three drugs in Preclinical. The Heart Valve Disease pipeline products include two routes of administration with the top ROA being Oral and three key molecule types in the Heart Valve Disease pipeline products market including Small Molecule, and Monoclonal Antibody.

Heart Valve Disease overview

Heart valve diseases are problems affecting one or more of the four valves in the heart, where the heart valve or valves do not open or close properly with every heartbeat, causing disruption of blood flow. Stenosis, regurgitation, and atresia are a few types of heart valve diseases. Signs and symptoms can range from mild to severe, including chest pain, irregular heartbeat (heart murmur), dizziness, shortness of breath, and tiredness. The causes of heart valve diseases are most often idiopathic and congenital, but aging and injury can also be a cause. The condition is diagnosed by ECG, 2D echo, chest x-ray, and CT scan. Heart valve diseases are treatable and treatment options include surgery for serious conditions, valvuloplasty, and management with medications.

For a complete picture of Heart Valve Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.